Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of KM-819 in healthy volunteers
NCT03022799Phase 1Completed
- Sponsor
- Kainos Medicine, Inc.
- Start
- Nov 2016
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Parkinson's disease (PD) comparing KM-819 with Placebo (2 arms). Primary endpoint: Number of Participants With Adverse Events. Started Nov 2016; status: completed.
02
Drugs
KM-819
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03022799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03022799.